Metronidazole CAS NO：443-48-1

Inhibitory Effect on Anaerobic Bacteria

Metronidazole exerts targeted bactericidal effects on anaerobic strains. It suppresses the synthesis of bacterial DNA and triggers lysis of pathogenic cells.

Broad-Spectrum Anti-Anaerobic Effect

It is clinically applicable to various anaerobic bacterial infections that affect the respiratory tract, digestive tract, abdominal cavity, skin tissue and central nervous system.

Gold-Standard Clinical Medicine

Since 1978, WHO has classified this product as the benchmark drug to cure oral anaerobic infectious diseases.

Widely Used in Clinical Regimens

It is extensively adopted in clinical treatment and preventive medication for severe anaerobic infectious diseases such as pericarditis and sepsis.

Contact Now E-Mail Telephone WhatsApp

Product Details

As a nitroimidazole-class antibacterial compound, metronidazole targets anaerobic microbes with high selectivity. After undergoing biological reduction inside pathogens, its transformed metabolites can block the synthetic process of bacterial DNA. Such mechanism will further stop microbial reproduction and damage bacterial survival capacity.

This medicine works against a wide range of anaerobic pathogenic strains, including Bacteroides fragilis, spindle-shaped Fusobacterium strains, Clostridium tetani, Peptococcus, Peptostreptococcus, as well as Giardia parasites.

Metronidazole CAS NO：443-48-1

Melting point	159-161 °C (lit.)
Boiling point	301.12°C (rough estimate)
density	1.3994 (rough estimate)
refractive index	1.5800 (estimate)
Fp	9℃
storage temp.	2-8°C
solubility	0.1 M, clear, faintly yellow
form	crystalline
pka	pKa 2.62(H2O,t =25±0.2,Iundefined) (Uncertain)
color	white to light yellow
Water Solubility	<0.1 g/100 mL at 20 ºC
Merck	146157
BRN	611683
BCS Class	1,3
Stability:	Stable. Incompatible with strong oxidizing agents.
InChIKey	VAOCPAMSLUNLGC-UHFFFAOYSA-N
LogP	-0.02
IARC	2B (Vol. 13, Sup 7) 1987
NIST Chemistry Reference	Metronidazole(443-48-1)
EPA Substance Registry System	Metronidazole (443-48-1)
Safety Information
Hazard Codes	Xn
Risk Statements	40-46-45-39/23/24/25-23/24/25-11
Safety Statements	36/37-45-53-16-7
WGK Germany	3
RTECS	NI5600000
F	8
HS Code	29332990
Hazardous Substances Data	443-48-1(Hazardous Substances Data)

Metronidazole CAS NO：443-48-1

Initially synthesized to cure trichomoniasis and delivers remarkable curative outcomes, this drug was later proven effective in treating anaerobic infectious lesions inside the oral cavity. Back in 1978, the WHO identified it as the primary medication to combat anaerobic pathogens, laying the foundation for its extensive clinical use in oral anaerobic disorder management.

In clinical practice, it serves both preventive and therapeutic purposes for anaerobic infections spreading across the respiratory tract, digestive tract, abdomen, pelvic cavity, skin, bones, joints and soft tissues. It is also widely prescribed to tackle critical illnesses such as pericarditis, bloodstream infections and central nervous system infectious diseases triggered by anaerobes.

Metronidazole CAS NO：443-48-1